Neurocrine Statistics
Want to see NBIX full AI Analyst Report?
Neurocrine (NBIX) Stock Statistics & Valuation Metrics
Total Valuation
Neurocrine has a market cap or net worth of $17.65B. The enterprise value is $14.58B.
- Market Cap
- $17.65B
- Enterprise Value
- $14.58B
Share Statistics
Neurocrine has 101,218,640 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 101,218,640
- Owned by Insiders
- 1.18%
- Owned by Institutions
- 67.75%
Financial Efficiency
Neurocrine’s return on equity (ROE) is 0.15 and return on invested capital (ROIC) is 10.80%.
- Return on Equity (ROE)
- 0.15
- Return on Assets (ROA)
- 0.10
- Return on Invested Capital (ROIC)
- 10.80%
- Return on Capital Employed (ROCE)
- 0.16
- Revenue Per Employee
- 1.14M
- Profits Per Employee
- 191.44K
- Employee Count
- 2,500
- Asset Turnover
- 0.62
- Inventory Turnover
- 0.76
Valuation Ratios
The current PE Ratio of Neurocrine is 24.47. Neurocrine’s PEG ratio is 0.40.
- PE Ratio
- 24.47
- PS Ratio
- 4.66
- PB Ratio
- 4.47
- Price to FCF
- 16.61
- Price to Operating Cash Flow
- 16.26
- PEG Ratio
- 0.40
Income Statement
In the last 12 months, Neurocrine had revenue of 2.86B and earned 478.60M in profits. Earnings per share was 4.81.
- Revenue
- 2.86B
- Gross Profit
- 2.81B
- Operating Income
- 619.10M
- Pretax Income
- 705.40M
- Net Income
- 478.60M
- EBITDA
- 666.60M
- Earnings Per Share (EPS)
- 4.81
Cash Flow
In the last 12 months, operating cash flow was 1.07B and capital expenditures -26.10M, giving a free cash flow of 1.04B billion.
- Operating Cash Flow
- 1.07B
- Free Cash Flow
- 1.04B
- Free Cash Flow per Share
- 10.23
Dividends & Yields
Neurocrine pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 6.06%
- Earnings Yield
- 4.08%
Stock Price Statistics
- Beta
- 0.53
- 52-Week Price Change
- 15.36%
- 50-Day Moving Average
- 147.79
- 200-Day Moving Average
- 148.57
- Relative Strength Index (RSI)
- 75.77
- Average Volume (3m)
- 1.31M
Important Dates
Neurocrine upcoming earnings date is Feb 11, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 02, 2026
- Next Earnings Date
- Feb 11, 2027
- Ex-Dividend Date
- ―
Financial Position
Neurocrine as a current ratio of 3.39, with Debt / Equity ratio of 12.77%
- Current Ratio
- 3.39
- Quick Ratio
- 3.30
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- -0.45
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Neurocrine has paid 226.80M in taxes.
- Income Tax
- 226.80M
- Effective Tax Rate
- 0.32
Enterprise Valuation
Neurocrine EV to EBITDA ratio is 17.85, with an EV/FCF ratio of 16.25.
- EV to Sales
- 4.56
- EV to EBITDA
- 17.85
- EV to Free Cash Flow
- 16.25
- EV to Operating Cash Flow
- 15.85
Balance Sheet
Neurocrine has $737.90M in cash and marketable securities with $392.30M in debt, giving a net cash position of $345.60M billion.
- Cash & Marketable Securities
- $737.90M
- Total Debt
- $392.30M
- Net Cash
- $345.60M
- Net Cash Per Share
- $3.41
- Tangible Book Value Per Share
- $11.68
Margins
Gross margin is 97.81%, with operating margin of 23.81%, and net profit margin of 18.98%.
- Gross Margin
- 97.81%
- Operating Margin
- 23.81%
- Pretax Margin
- 25.18%
- Net Profit Margin
- 18.98%
- EBITDA Margin
- 25.57%
- EBIT Margin
- 23.31%
Analyst Forecast
The average price target for Neurocrine is $206.74, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $206.74
- Price Target Upside
- 22.04% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 21
- Revenue Growth Forecast
- 37.98%
- EPS Growth Forecast
- 61.95%
Scores
- Smart Score
- 7
- AI Score
- 80
